Karen Barth Menzies Appointed to Co-Chair Taxotere Litigation Group of the AAJ

July 26, 2016

At the recent 2016 AAJ convention, Karen Barth Menzies, was appointed to serve as Co-Chair of the Taxotere Litigation Group, which is comprised of plaintiff attorneys throughout the country representing breast cancer patients who experienced permanent hair loss following the use of the Taxotere chemotherapy product. The litigation group will allow attorneys to collaborate on the status and developments of the ongoing Taxotere lawsuits filed against manufacturer Sanofi-Aventis.

The American Association for Justice (“AAJ) provides trial attorneys with information, professional support and a nationwide network that enables them to most effectively and expertly represent clients. AAJ Litigation Groups are critical tools for plaintiff attorneys confronting the overwhelming resources of corporate counsel in specific areas of practice or related to specific large-scale lawsuits. AAJ Litigation Groups facilitate collaboration among members on strategies, and create access to a powerful team of colleagues for assistance or advice when faced with unique challenges in complex litigation.

About Karen Barth Menzies

Karen focuses her practice on representing individuals who were injured through the use of defective drugs and medical devices, and is a member of our mass tort litigation practice. She serves in leadership positions in some of the largest pharmaceutical mass tort cases and she has been particularly focused on women’s health issues. In addition to the Taxotere lawsuits, Karen advocates for women who developed ovarian cancer after using talcum powder, and she represents individuals who experienced serious kidney injuries after taking PPI heartburn medications, including Nexium and Prilosec. She also represents children who experienced severe side effects after taking the widely-prescribed medication Risperdal. Karen has previously testified before FDA advisory boards as well as the California State Legislature on the safety concerns regarding the SSRI antidepressants and manufacturer misconduct.